In 2020, Jeffrey M. Leiden earned $14.50M in total compensation at Vertex Pharmaceuticals, including $1.12M salary and $13.34M in stock. Most recently acquired 7,209 shares in Feb 2025. Currently holds stock worth $70.42M. Has donated $1.14M in stock to charitable causes. Led Vertex Pharmaceuticals as CEO for 8 years.
Compensation History
Annual executive compensation data for Jeffrey M. Leiden, including salary, bonuses, and stock awards.
Year
2020
Total Compensation
$14.50M
Salary
$1.12M
Bonus
$0.00
Other
$43.14K
Salary
$1.12MBoard Justification
The compensation philosophy emphasizes performance alignment with company goals and shareholder interests, with a significant portion of compensation tied to performance metrics.
Bonus
$0.00Board Justification
No bonus was awarded for 2020 as per the compensation structure for the Executive Chairman role.
Other Compensation
$43.14KBoard Justification
Other compensation includes 401(k) match, life insurance premiums, and contributions to the Vertex Foundation Matching Gift Program.
Restricted Stock
Board Justification
The stock awards that vested in 2020 were based on performance metrics achieved in prior years, specifically related to Vertex's financial and operational goals.
Performance Metrics
Performance metrics included achieving financial targets related to CF net product revenues and advancing clinical programs.
Jeffrey M. Leiden
Ex-CEO of Vertex Pharmaceuticals
Education
B.A., Ph.D. in virology and M.D. from the University of Chicago
Field of Expertise
Healthcare & Life Sciences - Medicine
Sector of Economy
Healthcare
CEO of Vertex Pharmaceuticals for
8 years 1 month (Feb 2012 - Mar 2020)
Previous Experience
Managing Director at Clarus Ventures LLC, President and COO at Abbott Laboratories
Holdings
Track Jeffrey M. Leiden's stock holdings and portfolio value over time.
Total Stock Sold
$482.89M
$482.89M
2,683,566 VRTX shares
What if they kept their stock?
If Jeffrey M. Leiden didn't sell their stock, today they would have:
Extra VRTX2,683,566 shares worth $1.23B.
This is 154.11% and $744.20M more than what they got when they sold the stock.
Charitable Transactions
2,500 shares
VRTX
Recent Charitable Transactions
2,500 shares
VRTX
Dec 12, 2014
Charity
Insider Trading
Jeffrey M. Leiden's recent stock transactions, purchases, and sales filed with the SEC.
7,209 shares
VRTX
Feb 12, 2025
Received
15,414 shares
VRTX
Feb 4, 2025
Received
$1.89M
VRTX at $499.00/share
Aug 30, 2024
Sale
$3.78M
VRTX at $419.10/share
Feb 14, 2024
Sale
$1.42M
VRTX at $419.58/share
Feb 12, 2024
Sale
38,623 shares
VRTX
Feb 6, 2024
Received
$2.79M
VRTX at $419.07/share
Jan 8, 2024
Sale
$5.34M
VRTX at $399.80/share
Dec 13, 2023
Sale
$4.85M
VRTX at $374.00/share
Oct 16, 2023
Sale
$700.52K
VRTX at $349.56/share
May 5, 2023
Sale
Rivals
Compare Jeffrey M. Leiden with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Sundar Pichai
CEO of Alphabet Inc.
2024 Compensation
Stock
$51.70M
Salary
$2.02M
Bonus
$0.00
Other
$8.30M
Total Holdings
$399.66M
Andrew R. Jassy
CEO of Amazon
2024 Compensation
Stock
$38.48M
Salary
$365.00K
Bonus
$0.00
Other
$1.23M
Total Holdings
$2.14M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
David A. Ricks
CEO of Eli Lilly
2024 Compensation
Stock
$0.00
Salary
$1.69M
Bonus
$5.71M
Other
$351.69K
Total Holdings
$468.86M